News
NVS
158.20
+0.73%
1.15
AVDE: Diversified And Effective Active ETF At A Low Cost
Seeking Alpha · 5h ago
Oakmark International Strategy adds Unilever, Sanofi in Q4, exits Novartis
Seeking Alpha · 8h ago
International ETFs to Watch as Foreign Stock Markets Beat the US
NASDAQ · 9h ago
Novartis downgraded to Hold from Buy at DZ Bank
TipRanks · 13h ago
DZ BANK AG downgrades Novartis AG (NOVN) to a Hold
TipRanks · 1d ago
Weekly Report: what happened at NVS last week (0202-0206)?
Weekly Report · 1d ago
VIG vs. VYM vs. VYMI: Which Is Vanguard’s Best Dividend ETF for Reliable Passive Income?
TipRanks · 1d ago
Oakmark International Strategy Q4 2025 New Investments And Divestments
Seeking Alpha · 2d ago
Novartis breaks ground on new R&D center in San Diego
Seeking Alpha · 4d ago
Novartis baut neues globales Forschungszentrum in San Diego
Reuters · 4d ago
Novartis Breaks Ground on $23 Billion Biomedical Research Center in San Diego
Reuters · 4d ago
Novartis startet Bau eines globalen Biomedical Research Centers in San Diego
Reuters · 4d ago
Trump Trade: Argentina says U.S. to cut hundreds of tariffs
TipRanks · 4d ago
Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio.
Barron‘s · 4d ago
Blood Tests and Better-for-You Soda: Super Bowl Ads May Be Healthiest Yet
The Wall Street Journal · 4d ago
Kepler Capital Keeps Their Buy Rating on Novartis AG (NOVN)
TipRanks · 4d ago
Novartis Earnings Call: Record Margins Amid Generic Wave
TipRanks · 4d ago
Arrowhead steigert Umsatz im ersten Quartal 2026 auf 264,03 Mio. USD um mehr als das 100-Fache
Reuters · 5d ago
Arrowhead Pharmaceuticals Inc. posts Q1 revenue of USD 264.03 million, up over 100x
Reuters · 5d ago
Novartis price target lowered to CHF 132 from CHF 133 at Citi
TipRanks · 5d ago
More
Webull provides a variety of real-time NVS stock news. You can receive the latest news about Novartis through multiple platforms. This information may help you make smarter investment decisions.
About NVS
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.